HylaPharm is a pioneering university spinout company based in Lawrence, Kansas, dedicated to developing innovative cancer therapies for both humans and animals. Their groundbreaking approach focuses on reversing tumor-induced immune suppression, making cold tumors hot to the immune system, and increasing responsiveness to checkpoint inhibitors, which currently have limited success rates and potential side effects.
With a strong emphasis on research and development, HylaPharm has achieved significant milestones, including securing grants from the National Cancer Institute division of the National Institutes of Health and completing successful clinical trials on pet dogs with various types of cancer. Their cutting-edge treatments, such as Verisimod and NanoTor hyaluronan rapamycin nano conjugates, hold great promise for revolutionizing cancer treatment and eliminating the need for chemotherapy in the future.
Generated from the website